| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
3-Oxo-C10-HSL functions as a bacterial signaling molecule (autoinducer) that binds to and activates cognate transcriptional regulators, such as the LasR receptor, where it delivers 3.2-fold higher biosensor sensitivity (EC₅₀ 10 nM) than the native 3-oxo-C12-HSL. It acts as a critical high-Km substrate (0.12 mM) for quorum-quenching enzymes like AidB, which degrades AHLs. Beyond bacterial targets, it has anti-inflammatory activity in mammalian systems, suppressing the production of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α, without the confounding pro-inflammatory effects of other AHLs.
|
|---|---|
| ln Vitro |
3-Oxo-C10-HSL regulates bacterial gene expression, virulence factor production, biofilm formation, and synchronized group behavior in a concentration-dependent manner. It enables concentration-dependent biofilm modulation, enhancing biofilm formation at 10–20 µM and inhibiting it at 40–100 µM. It also suppresses LPS-induced NF-κB p65 phosphorylation, thereby reducing inflammatory responses in RAW264.7 macrophages. Additionally, genes associated with nitrogen metabolism, the TCA cycle, and glycolysis are more abundant in the 3-oxo-C10-HSL group, indicating strengthened metabolic coupling.
|
| ln Vivo |
3-Oxo-C10-HSL serves as a key molecular tool for studying bacterial communication mechanisms, pathogen virulence regulation, and screening anti-infection targets. As a quorum sensing signal, it plays a central role in regulating bacterial gene expression and cellular metabolism, controlling processes such as virulence, infection prevention, and biofilm formation. It has also been studied for its ability to inhibit LPS-induced inflammation in macrophages via the NF-κB signaling pathway, suggesting potential applications in host-pathogen interaction studies and anti-inflammatory research.
|
| Enzyme Assay |
Typical non-cell-based assays for 3-Oxo-C10-HSL involve studying its interaction with quorum-quenching enzymes such as AidB, where it serves as a substrate. The Michaelis constant (Km) for 3-oxo-C10-HSL is determined and compared to its unsubstituted counterpart, C10-HSL. Radioligand binding or biosensor-based assays are also employed to measure its affinity for receptors like LasR, using techniques such as fluorescence or luminescence detection. These cell-free systems allow for precise characterization of enzyme kinetics and receptor binding affinity without interference from cellular metabolism.
|
| Cell Assay |
Cellular assays for 3-Oxo-C10-HSL typically involve treating mammalian cells, such as RAW264.7 macrophages, with the compound at various concentrations (e.g., 1-100 µM) in the presence or absence of LPS. Inflammatory responses are assessed by measuring NF-κB p65 phosphorylation via Western blot, and cytokine levels (IL-6, IL-1β, TNF-α) are quantified by ELISA. For bacterial studies, cells are treated with the compound and effects on gene expression, biofilm formation, and virulence factor production are monitored. These cell-based systems enable detailed analysis of the compound's immunomodulatory and quorum sensing activities.
|
| Animal Protocol |
In vivo animal experiments for 3-Oxo-C10-HSL are not as extensively characterized as for other AHLs. However, it has been used in studies involving host-pathogen interactions, where it may modulate immune responses. Its anti-inflammatory activity, demonstrated by suppressing IL-6, IL-1β, and TNF-α, suggests potential for use in animal models of inflammation. For quorum sensing studies, animal models infected with V. anguillarum or other AHL-producing bacteria could be used to assess the compound's effects on virulence and infection outcomes, though such specific protocols are not widely detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3-Oxo-C10-HSL are limited. As a small, lipophilic molecule with a molecular weight of 269.34 g/mol and a LogP of 0.96, it would be expected to have moderate oral bioavailability and good tissue distribution. It is likely metabolized by esterases and other enzymes that hydrolyze the lactone ring or degrade the acyl chain. Quorum-quenching enzymes such as AidB can degrade this AHL, suggesting it is susceptible to enzymatic hydrolysis. However, detailed ADME parameters including Cmax, Tmax, half-life, and bioavailability are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-Oxo-C10-HSL are limited. As a bacterial signaling molecule, it is not intended for human therapeutic use and is classified as a research compound. It is available from suppliers for research use only and is not for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound. At high concentrations (40–100 µM), it inhibits biofilm formation, which may indicate potential bactericidal or bacteriostatic effects, but comprehensive toxicological studies have not been reported.
|
| References |
|
| Additional Infomation |
N-(3-oxo-decanoyl)-homoserine lactone is an N-acyl amino acid. 3-oxo-N-[(3s)-2-oxotetrahydrofuran-3-Yl]decanoamide has been reported in Aliivibrio fischeri and Azospirillum lipoferum with available data.
3-Oxo-C10-HSL is exclusively a research tool for studying bacterial quorum sensing, biofilm regulation, and host-pathogen interactions. It has no clinical applications or approved drug status. It is supplied as a high-purity (≥98%) compound from commercial vendors for use in mechanistic studies of cell-cell communication and as an optimal calibrant for trace-level detection in LasR biosensor systems. It is also used in studies of bacterial gene expression, virulence regulation, and as a substrate for quorum-quenching enzymology. It is not approved for any clinical indication. |
| Molecular Formula |
C14H23NO4
|
|---|---|
| Molecular Weight |
269.34
|
| Exact Mass |
269.162
|
| CAS # |
147795-40-2
|
| PubChem CID |
10221060
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
503.2±50.0 °C at 760 mmHg
|
| Flash Point |
258.1±30.1 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.484
|
| LogP |
0.96
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
19
|
| Complexity |
327
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCC(=O)CC(=O)NC1CCOC1=O
|
| InChi Key |
KYGIKEQVUKTKRR-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C14H23NO4/c1-2-3-4-5-6-7-11(16)10-13(17)15-12-8-9-19-14(12)18/h12H,2-10H2,1H3,(H,15,17)/t12-/m0/s1
|
| Chemical Name |
3-oxo-N-[(3S)-2-oxooxolan-3-yl]decanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7128 mL | 18.5639 mL | 37.1278 mL | |
| 5 mM | 0.7426 mL | 3.7128 mL | 7.4256 mL | |
| 10 mM | 0.3713 mL | 1.8564 mL | 3.7128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
